Overview Dividends

(AMPH) Amphastar P - Ratings and Ratios

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US03209R1032

Enoxaparin, Insulin, Glucagon, Naloxone, Epinephrine

AMPH EPS (Earnings per Share)

EPS Growth (3Y CAGR): 9.20%
EPS Trend (3Y Correlation): 36.7%

AMPH Revenue

Revenue Growth (3Y CAGR): 13.62%
Revenue Trend (3Y Correlation): 76.7%

Risk via 10d forecast
Volatility	45.2%
Value at Risk 5%th	69.0%

Reward
Sharpe Ratio	-1.22
Alpha Jensen	-57.08

Character
Hurst Exponent	0.622
Beta	0.917

Drawdowns 3y
Max DD	68.28%
Mean DD	30.29%

Description: AMPH Amphastar P August 21, 2025

Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) is a US-based company operating in the Pharmaceuticals sub-industry. The companys market capitalization stands at approximately $1.1 billion, indicating a mid-cap status. With a Return on Equity (ROE) of 19.37%, Amphastar demonstrates a relatively strong ability to generate profits from shareholder equity.

The stocks Price-to-Earnings (P/E) ratio is 8.92, suggesting that the company may be undervalued compared to its earnings. This could be an attractive feature for value investors. However, the forward P/E ratio is not available, potentially due to a lack of analyst estimates or significant variability in earnings forecasts.

Key drivers for Amphastars stock performance may include the companys product portfolio, pipeline developments, and competitive positioning within the pharmaceutical industry. Investors should monitor revenue growth, gross margin trends, and research and development (R&D) expenses to gauge the companys operational performance. Additionally, keeping track of regulatory updates and industry trends will be crucial in assessing Amphastars future prospects.

From a technical perspective, the stocks beta of 0.76 indicates relatively lower volatility compared to the broader market. This, combined with its current price near the 52-week high, suggests that Amphastars stock may be experiencing a degree of stability. Investors should continue to monitor moving averages, such as the SMA20 and SMA50, to identify potential trend reversals or continuations.

AMPH Stock Overview

Market Cap in USD	1,104m
Sub-Industry	Pharmaceuticals
IPO / Inception	2014-06-25
Return 12m vs S&P 500	-49.7%
Analyst Rating	3.67 of 5

AMPH Dividends

Currently no dividends paid

AMPH Growth Ratios

CAGR	-0.55%
CAGR/Max DD Calmar Ratio	-0.01
CAGR/Mean DD Pain Ratio	-0.02
Current Volume	685.8k
Average Volume	390.8k

Piotroski VR‑10 (Strict, 0-10) 5.0

Net Income (111.6m TTM) > 0 and > 6% of Revenue (6% = 43.4m TTM)

FCFTA 0.07 (>2.0%) and ΔFCFTA -4.21pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)

NWC/Revenue 60.04% (prev 53.66%; Δ 6.38pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)

CFO/TA 0.09 (>3.0%) and CFO 152.3m > Net Income 111.6m (YES >=105%, WARN >=100%)

Net Debt (440.3m) to EBITDA (204.6m) ratio: 2.15 <= 3.0 (WARN <= 3.5)

Current Ratio 3.12 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)

Outstanding Shares last Quarter (47.7m) change vs 12m ago -8.07% (target <= -2.0% for YES)

Gross Margin 49.36% (prev 52.41%; Δ -3.05pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)

Asset Turnover 45.05% (prev 46.67%; Δ -1.63pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)

Interest Coverage Ratio 5.27 (EBITDA TTM 204.6m / Interest Expense TTM 25.3m) >= 6 (WARN >= 3)

Altman Z'' 4.28

(A) 0.26 = (Total Current Assets 639.5m - Total Current Liabilities 205.2m) / Total Assets 1.67b

(B) 0.39 = Retained Earnings (Balance) 642.5m / Total Assets 1.67b

(D) 0.72 = Book Value of Equity 637.2m / Total Liabilities 889.5m

Total Rating: 4.28 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 70.62

1. Piotroski 5.0pt = 0.0

2. FCF Yield 7.64% = 3.82

3. FCF Margin 15.66% = 3.91

4. Debt/Equity 0.85 = 2.16

5. Debt/Ebitda 2.15 = -0.30

6. ROIC - WACC (= 1.77)% = 2.21

7. RoE 14.80% = 1.23

8. Rev. Trend 76.69% = 5.75

9. EPS Trend 36.70% = 1.84

What is the price of AMPH shares?

As of November 13, 2025, the stock is trading at USD 27.83 with a total of 685,779 shares traded.
Over the past week, the price has changed by +9.96%, over one month by +18.38%, over three months by -8.30% and over the past year by -41.67%.

Is Amphastar P a good stock to buy?

Partly, yes. Based on ValueRay´s Fundamental Analyses, Amphastar P (NASDAQ:AMPH) is currently (November 2025) ok to buy, but has to be watched. It has a ValueRay Fundamental Rating of 70.62 and therefor a somewhat positive outlook according to the companies health.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of AMPH is around 22.50 USD . This means that AMPH is currently overvalued and has a potential downside of -19.15%.

Is AMPH a buy, sell or hold?

Amphastar P has received a consensus analysts rating of 3.67. Therefor, it is recommend to hold AMPH.

Strong Buy: 2
Buy: 0
Hold: 4
Sell: 0
Strong Sell: 0

What are the forecasts/targets for the AMPH price?

Issuer	Target	Up/Down from current
Wallstreet Target Price	32.3	16.2%
Analysts Target Price	32.3	16.2%
ValueRay Target Price	24.6	-11.7%

AMPH Fundamental Data Overview November 11, 2025

Market Cap USD = 1.10b (1.10b USD * 1.0 USD.USD)
P/E Trailing = 10.6327
P/S = 1.5266
P/B = 1.6278
P/EG = 2.77
Beta = 0.917
Revenue TTM = 723.3m USD
EBIT TTM = 133.2m USD
EBITDA TTM = 204.6m USD
Long Term Debt = 601.6m USD (from longTermDebt, last fiscal year)
Short Term Debt = 8.75m USD (from shortTermDebt, last quarter)
Debt = 656.8m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 440.3m USD (from netDebt column, last quarter)
Enterprise Value = 1.48b USD (1.10b + Debt 656.8m - CCE 278.6m)
Interest Coverage Ratio = 5.27 (Ebit TTM 133.2m / Interest Expense TTM 25.3m)
FCF Yield = 7.64% (FCF TTM 113.3m / Enterprise Value 1.48b)
FCF Margin = 15.66% (FCF TTM 113.3m / Revenue TTM 723.3m)
Net Margin = 15.43% (Net Income TTM 111.6m / Revenue TTM 723.3m)
Gross Margin = 49.36% ((Revenue TTM 723.3m - Cost of Revenue TTM 366.3m) / Revenue TTM)
Gross Margin QoQ = 51.42% (prev 49.59%)
Tobins Q-Ratio = 0.89 (Enterprise Value 1.48b / Total Assets 1.67b)
Interest Expense / Debt = 0.96% (Interest Expense 6.28m / Debt 656.8m)
Taxrate = 19.35% (4.16m / 21.5m)
NOPAT = 107.4m (EBIT 133.2m * (1 - 19.35%))
Current Ratio = 3.12 (Total Current Assets 639.5m / Total Current Liabilities 205.2m)
Debt / Equity = 0.85 (Debt 656.8m / totalStockholderEquity, last quarter 776.7m)
Debt / EBITDA = 2.15 (Net Debt 440.3m / EBITDA 204.6m)
Debt / FCF = 3.89 (Net Debt 440.3m / FCF TTM 113.3m)
Total Stockholder Equity = 754.5m (last 4 quarters mean from totalStockholderEquity)
RoA = 6.70% (Net Income 111.6m / Total Assets 1.67b)
RoE = 14.80% (Net Income TTM 111.6m / Total Stockholder Equity 754.5m)
RoCE = 9.82% (EBIT 133.2m / Capital Employed (Equity 754.5m + L.T.Debt 601.6m))
RoIC = 7.94% (NOPAT 107.4m / Invested Capital 1.35b)
WACC = 6.18% (E(1.10b)/V(1.76b) * Re(9.39%) + D(656.8m)/V(1.76b) * Rd(0.96%) * (1-Tc(0.19)))
Discount Rate = 9.39% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -100.0 | Cagr: -5.17%
[DCF Debug] Terminal Value 76.59% ; FCFE base≈136.0m ; Y1≈161.7m ; Y5≈253.3m
Fair Price DCF = 74.07 (DCF Value 3.40b / Shares Outstanding 46.0m; 5y FCF grow 20.13% → 3.0% )
EPS Correlation: 36.70 | EPS CAGR: 9.20% | SUE: 0.47 | # QB: 0
Revenue Correlation: 76.69 | Revenue CAGR: 13.62% | SUE: 1.22 | # QB: 1

Additional Sources for AMPH Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle